{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:11:43Z","timestamp":1792192303551,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3 Part 1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.juro.2016.09.088","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T05:03:52Z","timestamp":1475643832000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status"],"prefix":"10.1097","volume":"197","author":[{"given":"Sarah R.","family":"Ottenhof","sequence":"first","affiliation":[{"name":"Department of Urological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa S.","family":"Djajadiningrat","sequence":"additional","affiliation":[{"name":"Department of Urological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene H.","family":"Thygesen","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Horenblas","sequence":"additional","affiliation":[{"name":"Department of Urological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina S.","family":"Jordanova","sequence":"additional","affiliation":[{"name":"Center Gynecological Oncology Amsterdam, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.09.088_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bju.12993","article-title":"Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival","volume":"117","author":"Kirrander","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2016.09.088_bib2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.urolonc.2006.08.029","article-title":"Incidence trends in primary malignant penile cancer","volume":"25","author":"Barnholtz-Sloan","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib3","first-page":"7201","article-title":"Contemporary management of penile cancer: greater than 15 year MSKCC experience","volume":"21","author":"Moses","year":"2014","journal-title":"Can J Urol"},{"key":"10.1016\/j.juro.2016.09.088_bib4","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.juro.2016.09.088_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2016.09.088_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.juro.2016.09.088_bib7","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.juro.2016.09.088_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.juro.2016.09.088_bib9","first-page":"165","article-title":"Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma","volume":"117","author":"Kim","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.juro.2016.09.088_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.juro.2016.09.088_bib11","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2016.09.088_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.juro.2014.08.087","article-title":"Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.09.088_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.juro.2014.11.057","article-title":"Classic and nonclassic HLA class I expression in penile cancer and relation to HPV status and clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.09.088_bib15","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.juro.2016.09.088_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase ii trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.juro.2016.09.088_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.juro.2016.09.088_bib20","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.4049\/jimmunol.181.9.5842","article-title":"Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development","volume":"181","author":"Kryczek","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.juro.2016.09.088_bib21","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","article-title":"Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade","volume":"21","author":"Taube","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2016.09.088_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaoncol.2015.6326","article-title":"Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva","volume":"2","author":"Howitt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"268","author":"Ilie","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.juro.2016.09.088_bib24","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1007\/s13277-015-4652-z","article-title":"Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma","volume":"37","author":"Safaei","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.juro.2016.09.088_bib25","doi-asserted-by":"crossref","first-page":"8944","DOI":"10.18632\/oncotarget.6884","article-title":"Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.juro.2016.09.088_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.juro.2016.09.088_bib27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2016.09.088_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00262-014-1519-x","article-title":"PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients","volume":"63","author":"Sun","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2016.09.088_bib29","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2016.09.088_bib30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716314070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716314070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.09.088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:36:16Z","timestamp":1651206976000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.09.088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":30,"journal-issue":{"issue":"3 Part 1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1016\/j.juro.2016.09.088"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.09.088","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.09.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}